{"product_id":"alkermes-five-forces-analysis","title":"Alkermes Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cpalkermes faces moderate supplier power high regulatory barriers and intense rivalry driven by innovation pricing pressures while buyer negotiation substitutes present emerging risks that could reshape margins.\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Alkermes’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/palkermes\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of specialized API manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes depends on a small set of specialized API makers for its CNS drugs, and roughly 60–70% of critical APIs in the sector come from single-source or dual-source suppliers as of 2024, raising concentration risk.\u003c\/p\u003e\n\u003cp\u003eEven when raw inputs are commodity-like, regulator approvals (FDA\/EMA) and batch validation add 6–12+ months and millions in qualifying costs, so switching suppliers is slow and costly.\u003c\/p\u003e\n\u003cp\u003eThat regulatory friction gives suppliers moderate pricing and delivery leverage, reflected in reported COGS variability of ±3–5% for Alkermes’ pipeline products in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on contract manufacturing organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlkermes relies on contract manufacturing organizations (CMOs) for key drug substance and product steps to cut fixed costs and retain flexibility; switching a biologics line can cost tens of millions and 9–18 months, giving CMOs leverage.\u003c\/p\u003e\n\u003cp\u003eCMOs’ technical know-how and regulatory dossiers raise bargaining power; Alkermes reported 38% of COGS tied to outsourced manufacturing in 2024, so supplier hold is material.\u003c\/p\u003e\n\u003cp\u003eGlobal demand for advanced biomanufacturing rose ~22% in 2024 and is projected up to late 2025, strengthening established CMOs’ negotiating position and pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to specialized scientific and technical talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe supply of specialized researchers and clinical experts is crucial for Alkermes' R\u0026amp;D in CNS therapies; with US biotech employment up 6.2% in 2024 and median life-science scientist pay at ~$120,000, competition raises bargaining power and lifts labor costs. Higher compensation and sign-on packages—Alkermes reported R\u0026amp;D spend of $520M in 2024—can slow timelines and raise per-project costs, affecting innovation velocity and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary technology and intellectual property licenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlkermes relies on licensed tech from universities and biotechs; licensors control key patents for its proprietary delivery systems, giving suppliers strong leverage.\u003c\/p\u003e\n\u003cp\u003eWhen a license is central to a drug’s efficacy, royalty and milestone talks skew toward the IP holder; typical biotech royalties range 5–15% and upfronts can hit $10–50M, raising COGS and margin pressure for Alkermes.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eKey fact: licensors control essential patents\u003c\/li\u003e\n\u003cli\u003eRoyalty range 5–15%, upfronts $10–50M (industry 2024–25)\u003c\/li\u003e\n\u003cli\u003eNegotiation power rises if tech is central to efficacy\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory compliance and quality standards of raw materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSuppliers of chemical precursors must follow strict Good Manufacturing Practice (GMP) to meet FDA and EMA rules; a single supplier quality failure can trigger production halts, FDA warning letters, or batch recalls that cost millions.\u003c\/p\u003e\n\u003cp\u003eAlkermes therefore keeps long-term contracts and audits with proven vendors, limiting its leverage to force price cuts without risking supply disruptions and regulatory sanctions.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a 2024 industry estimate shows GMP-related supply failures can delay launches by 6–12 months and incur direct costs of $5–20M per event.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP required for FDA\/EMA\u003c\/li\u003e\n\u003cli\u003eSupply failure → 6–12 month delays\u003c\/li\u003e\n\u003cli\u003eDirect cost $5–20M per failure\u003c\/li\u003e\n\u003cli\u003eLong-term contracts limit price pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers Hold Leverage: Single-Source APIs, High Outsourcing \u0026amp; Costly GMP Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-strong power: single\/dual-source APIs (60–70% sector-wide in 2024), 6–12+ month supplier qualification, Alkermes 38% COGS outsourced (2024), R\u0026amp;D $520M (2024) raising labor leverage, licensors demand 5–15% royalties and $10–50M upfronts, GMP failures cost $5–20M and 6–12 month delays, long-term contracts limit Alkermes’ price pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI single\/dual-source\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced COGS\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$520M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP failure cost\/delay\u003c\/td\u003e\n\u003ctd\u003e$5–20M \/ 6–12 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces for Alkermes, uncovering competitive drivers, buyer and supplier influence, entry barriers, substitutes, and emerging threats to its market share and profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces summary for Alkermes—quickly spot competitive pressures and prioritize strategic responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of pharmacy benefit managers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThree PBMs—CVS Caremark (Caremark), Express Scripts (Cigna), and Optum Rx (UnitedHealth)—collectively manage ~80% of US prescription claims as of 2024, giving them outsized rebate leverage against drugmakers like Alkermes. These PBMs set formularies and tier placement, so exclusion or higher copay tiering for Lybalvi (approved 2022) can cut volume sharply; Alkermes reported Lybalvi net sales pressure from access and rebates in its 2024 10-K. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare programs and pricing legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFederal and state governments are major buyers of CNS drugs through Medicare and Medicaid, which covered about 72 million people on Medicaid and 64 million on Medicare in 2024; that scale gives them leverage over Alkermes’ pricing.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 new price negotiation mandates and inflation-related caps require manufacturers to justify prices and face possible rebates; CMS negotiation could affect drugs with annual U.S. sales above $100m.\u003c\/p\u003e\n\u003cp\u003eThe government’s power to set reimbursement rates and demand higher rebates can compress Alkermes’ margins—U.S. government payers accounted for roughly 40% of prescription drug spending in recent CMS reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge scale hospital systems and psychiatric networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsolidated hospital systems and psychiatric networks act as centralized buyers for injectables like Aristada, with US hospital health systems accounting for roughly 60% of inpatient psychiatric discharges in 2023, boosting their bargaining clout.\u003c\/p\u003e\n\u003cp\u003eThese large purchasers leverage annual patient volumes—some systems treat 10,000+ behavioral health patients—to demand discounts, formulary placement, and service contracts, pressuring manufacturers' margins.\u003c\/p\u003e\n\u003cp\u003eTheir influence is strongest in institutional settings where standardized protocols and group purchasing organizations (GPOs) control procurement; GPO-negotiated rebates can exceed 20% for high-volume biologics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of patient advocacy groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups, though not direct buyers, sway insurers and governments; 2024 surveys show 62% of payers cite advocacy pressure as a factor in formulary decisions for CNS drugs.\u003c\/p\u003e\n\u003cp\u003eThey drive policy and public opinion, pushing coverage for innovative schizophrenia and bipolar therapies, evidenced by 2023 US Congressional hearings that led to expanded access pilots.\u003c\/p\u003e\n\u003cp\u003eAlkermes must engage these groups to get its therapies recognized by payers who make the final purchase decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of payers report advocacy influence (2024 survey)\u003c\/li\u003e\n\u003cli\u003e2023 hearings led to coverage pilots\u003c\/li\u003e\n\u003cli\u003eDirect engagement boosts formulary acceptance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice sensitivity in the genericized CNS market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatients and providers increasingly favor lower-cost generics; in the US generics made up 90% of prescriptions by volume in 2024, pressuring Alkermes to justify branded premiums for CNS drugs.\u003c\/p\u003e\n\u003cp\u003eAlkermes must supply strong clinical evidence and patient support programs—eg, adherence services and copay assistance—to maintain price elasticity-sensitive buyers.\u003c\/p\u003e\n\u003cp\u003eWith 20+ approved psychiatric alternatives for major indications, buyers can switch if value-to-price is poor, raising churn risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenerics = 90% Rx volume (US, 2024)\u003c\/li\u003e\n\u003cli\u003e20+ psychiatric alternatives\u003c\/li\u003e\n\u003cli\u003eRequires clinical data + patient support\u003c\/li\u003e\n\u003cli\u003eHigh price sensitivity → switch risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers dominate US drug market: PBMs, government, generics drive pricing and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge PBMs (Caremark, Express Scripts, Optum Rx) control ~80% US scripts (2024), Medicare\/Medicaid cover ~136M enrollees (2024), and government payers drive ~40% of drug spend; consolidated hospitals\/GPOs and 20+ alternatives raise switching risk; generics = 90% of US Rx volume (2024), advocacy influences 62% of payer decisions—altogether giving buyers strong leverage to demand rebates, access restrictions, and patient-support services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop PBMs\u003c\/td\u003e\n\u003ctd\u003e~80% script share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare+Medicaid\u003c\/td\u003e\n\u003ctd\u003e~136M enrollees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt share of spend\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e90% Rx volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer influence by advocacy\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAlkermes Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Alkermes Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups, fully formatted and ready to use.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the same professionally written deliverable available for instant download upon payment, containing complete force-by-force assessment and strategic implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747053384057,"sku":"alkermes-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alkermes-five-forces-analysis.png?v=1772194642","url":"https:\/\/matrixbcg.com\/products\/alkermes-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}